Trial Profile
An Open-Label, Single-Sequence Study to Assess the Effect of Multiple Doses of Tasimelteon on the Cytochrome P450 3A4 and 2C8 Enzymes Using Midazolam and Rosiglitazone as Substrates in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Tasimelteon (Primary) ; Midazolam; Rosiglitazone
- Indications Circadian rhythm sleep disorders; Insomnia; Major depressive disorder; Seizures; Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Vanda Pharmaceuticals
- 25 Aug 2011 Status changed from recruiting to completed, as reported by ClinicalTrials.gov.
- 12 Aug 2011 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 01 Aug 2011 New trial record